TRAVERE THERAPEUTICS INC TVTX 深 滬
等待開盤 12-16 09:30:00 美东时间
34.76
-0.070
-0.20%
華盛通- 最 高36.243
- 今 開35.14
- 成交量 162.10万股
- 最 低 34.43
- 昨 收 34.83
- 總市值 30.98亿
- 52周最高 37.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 12.91
- 委 比 -43.73%
- 總股本 8913.87万
- 歷史最高 37.50
- 量 比 1.19
- 振 幅 5.21%
- 歷史最低 0.90
- 每 手 1
- 風險率 6.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
12-01 14:33
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $47 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $47 price target.
11-28 19:57
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alphatec Holdings (NASDAQ:ATEC) shares rose 21.7% to $19.88 during Fri...
10-31 20:10
美股盘后 | TRAVERE THERAPEUTICS涨11.40%
TRAVERE THERAPEUTICS将于10月30日公布2025年季度财报，市场预期每股亏损0.17美元，营收1.0501亿美元。作为生物制药公司，其财务表现将是评估公司盈利能力和发展前景的重要指标。
10-31 05:02
Travere Therapeutics shares are trading higher after the company reported better-than-expected Q3 sales results.
Travere Therapeutics shares are trading higher after the company reported bette...
10-31 04:35
Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
Novartis Strengthens Kidney Disease Pipeline With Promising Data
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026.
10-16 22:50
Travere Therapeutics shares are trading higher. Guggenheim issued a Buy rating on the stock and a price target of $47.
Travere Therapeutics shares are trading higher. Guggenheim issued a Buy rating ...
10-07 01:02
